CELG-RI supply chain intelligence for BRISTOL MYERS SQUIBB CO: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
BRISTOL MYERS SQUIBB CO (CELG-RI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship fro… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from … |
| CUE | Cue Biopharma, Inc. | 72% | Reciprocal relationship from CUE graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CUE graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CU… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DY… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: ay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legis… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies fo… |
| HOWL | Werewolf Therapeutics, Inc. | 72% | Reciprocal relationship from HOWL graph: , the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| OCUL | Ocular Therapeutix, Inc. | 72% | Reciprocal relationship from OCUL graph: uman use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the … |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commerci… |
| PPBT | Purple Biotech Ltd | 72% | Reciprocal relationship from PPBT graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: letion of these trials and adversely affect our ability to advance the de… |
| SMMT | Summit Therapeutics Inc. | 72% | Reciprocal relationship from SMMT graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, La… |
| TRVI | Trevi Therapeutics, Inc. | 72% | Reciprocal relationship from TRVI graph: inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsible for assessing non-clinical (e.g., economi… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from … |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from XLO graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from XL… |
| ZBIO | Zenas BioPharma, Inc. | 72% | Reciprocal relationship from ZBIO graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced sol… |
| CUE | Cue Biopharma, Inc. | 72% | Reciprocal relationship from CUE graph: experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become inte… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: ay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legis… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti… |
| HOWL | Werewolf Therapeutics, Inc. | 72% | Reciprocal relationship from HOWL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: ization will cease to be renewed. We and our contract manufacturers are s… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intel… |
| OCUL | Ocular Therapeutix, Inc. | 72% | Reciprocal relationship from OCUL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from … |
| PFE | Pfizer Inc. | 72% | Reciprocal relationship from PFE graph: . $ Granted Exercised Forfeited ( ) Expired ( ) Outstanding, December 31, 2025 $ Vested and expected to vest, December 31, 2025 (b) Exercisable, December 31, 2… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks assoc… |
| PPBT | Purple Biotech Ltd | 72% | Reciprocal relationship from PPBT graph: letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. Even if we can enroll a sufficient number of… |
| RNTX | Rein Therapeutics Inc. | 72% | Reciprocal relationship from RNTX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from RNTX graph: development stage. Manufacturing We do not own or operate manufacturing f… |
| SMMT | Summit Therapeutics Inc. | 72% | Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”).… |
| TRVI | Trevi Therapeutics, Inc. | 72% | Reciprocal relationship from TRVI graph: inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsible for assessing non-clinical (e.g., economi… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: and EO 14070, Continuing to Strengthen Americans’ Access to Affordable, Quality Health Coverage) where were designed to further implement the ACA. We anticipa… |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) … |
| ZBIO | Zenas BioPharma, Inc. | 72% | Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier,… |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| PLRX | Pliant Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CUE | Cue Biopharma, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| PFE | Pfizer Inc. | 100.00 | 1 | ['customer'] |
| XLO | Xilio Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TRVI | Trevi Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| GNLX | Genelux Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| INAB | IN8bio, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| RNTX | Rein Therapeutics Inc. | 100.00 | 1 | ['customer'] |
| OCUL | Ocular Therapeutix, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| PPBT | Purple Biotech Ltd | 100.00 | 1 | ['customer', 'supplier'] |
| VYGR | Voyager Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ZBIO | Zenas BioPharma, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SMMT | Summit Therapeutics Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CELUW | Celularity Inc | 100.00 | 1 | ['supplier'] |
| DIDIY | DiDi Global Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| CLYM | Climb Bio, Inc. | 50.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 50.00 | 2 |